摘要目的：探讨AT序列特异性结合蛋白2（ SATB2）在骨肉瘤病理诊断及鉴别诊断中的价值。方法收集安徽科大学第一附属医院2008至2014年间确诊的47例骨肉瘤（普通型骨肉瘤、小细胞性骨肉瘤、髓内高分化骨肉瘤和其他类型骨肉瘤）、5例骨母细胞瘤、4例纤维结构不良、5例骨化性肌炎、10例软骨母细胞瘤、8例软骨肉瘤、5例Ewing肉瘤、5例未分化多形性肉瘤、6例纤维肉瘤和2例平滑肌肉瘤，采用免疫组织化学EnVision法分别检测SATB2蛋白在这些病变中表达的情况。结果 SATB2在骨肉瘤中阳性表达率为83.0％（39／47），在骨母细胞瘤中阳性表达比例为5／5，在骨化性肌炎中阳性表达比例为5／5，在软骨母细胞瘤中阳性表达比例为2／10，但在纤维结构不良、软骨肉瘤、Ewing肉瘤和骨原发性梭形细胞肉瘤（未分化多形性肉瘤、纤维肉瘤和平滑肌肉瘤）中均为阴性。结论 SATB2做为可靠的成骨细胞标志物，对于鉴别骨肉瘤和其他非成骨性肉瘤具有重要意义。但值得注意的是SATB2对于区分骨肉瘤和其他成骨性病变意义有限。

abstractsObjective To investigate the role of SATB2 in the pathological diagnosis and differential diagnosis of osteosarcoma.Methods Immunostaining of SATB2 was performed in 47 cases of osteosarcomas, 5 osteoblastomas, 4 fibrous dysplasias, 5 myositis ossificans, 10 chondroblastomas, 8 chondrosarcomas, 5 Ewing sarcomas, 5 undifferentiated pleomorphic sarcomas, 6 fibrosarcomas and 2 leiomyosarcomas.Results All osteoblastomas (5/5) and myositis ossificans (5/5), 83.0%(39/47) of osteosarcomas and 2/10 of chondroblastomas showed nuclear immunoreactivity for SATB2.SATB2 staining was negative in all cases of fibrous dysplasia, chondrosarcomas, Ewing sarcomas and all bone primary spindle cell sarcomas ( undifferentiated pleomorphic sarcoma, fibrosarcoma and leiomyosarcoma ) .Conclusion SATB2 is a reliable osteoblastic marker for differential diagnosis of osteosarcoma and non-osteoid sarcoma, although with a limited role in separating osteosarcoma from non-malignant osteoblastic lesions.